The trial is sponsored by the Chinese PLA General Hospital and aims to evaluate the safety and efficacy of autologous CD19-targeting STAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of existing therapies, this innovative approach could capture significant market share in the CAR-T and TCR-T therapy landscape. The competitive landscape includes established CAR-T therapies like Kymriah and Yescarta, which have demonstrated efficacy but also significant toxicity. The STAR-T approach may offer a differentiated profile with potentially lower toxicity and improved efficacy, making it an attractive option for patients with limited treatment options. Diligence should focus on regulatory pathways, potential partnerships, and the scalability of manufacturing processes for STAR-T cells.